AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2243674 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac ophthalmic solution (NSAID)
Number of subjects: 50
Study 2243674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 80526 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 11
Study 80526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 29621113 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated Power Group (RPG)
Number of subjects: 20
Study 29621113 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CON)
Number of subjects: 20
Study 28796316 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) 8 mg/kg
Number of subjects: 18
Study 28796316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 28796316 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) PMN-'low'
Number of subjects: 18
Study 26154185 — intervention group
Group type: EXPERIMENTAL
Intervention: Nociception Level (NoL) index during moderate noxious stimulation (skin incision)
Number of subjects: 72
Study 26154185 — intervention group
Group type: EXPERIMENTAL
Intervention: Nociception Level (NoL) index during intense noxious stimulation (intubation)
Number of subjects: 72
Study 26154185 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Rate (HR) during moderate noxious stimulation (skin incision)
Number of subjects: 72
Study 26154185 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean Arterial Pressure (MAP) during moderate noxious stimulation (skin incision)
Number of subjects: 72
Study 26154185 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Rate (HR) during intense noxious stimulation (intubation)
Number of subjects: 72
Study 26154185 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean Arterial Pressure (MAP) during intense noxious stimulation (intubation)
Number of subjects: 72
Study 26154185 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver Operating Characteristic (ROC) curve for ΔNoL
Number of subjects: 72
Study 23657629 — intervention group
Group type: EXPERIMENTAL
Intervention: Melanoma vaccine in incomplete Freund's adjuvant (IFA)
Number of subjects: 45
Study 23657629 — intervention group
Group type: COMPARATOR
Intervention: Incomplete Freund's adjuvant (IFA) only
Number of subjects: 45
Study 21177791 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily transdermal DHT gel
Number of subjects: 31
Study 21177791 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 31
Study 19725341 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascia iliaca compartment block with 0.45% ropivacaine at a dosage of 0.3 mL/kg (maximum dose, 30 mL)
Number of subjects: 41
Study 19725341 — intervention group
Group type: COMPARATOR
Intervention: Control group (no block performed)
Number of subjects: 41
Study 19725341 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascia iliaca compartment block
Number of subjects: 41
Study 17623694 — intervention group
Group type: EXPERIMENTAL
Intervention: Iclaprim (AR-100) 1.6 mg/kg intravenous infusion
Number of subjects: 0
Study 14690867 — intervention group
Group type: EXPERIMENTAL
Intervention: Care consultation (multi-component telephone intervention) in addition to usual managed care services
Number of subjects: 0
Study 14690867 — intervention group
Group type: COMPARATOR
Intervention: Usual managed care services
Number of subjects: 0
Study 11222075 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided detection (CAD) system
Number of subjects: 106
Study 11222075 — intervention group
Group type: COMPARATOR
Intervention: Mammographers without CAD
Number of subjects: 106
Study 11222075 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammographers with CAD
Number of subjects: 106
Study 9605364 — intervention group
Group type: EXPERIMENTAL
Intervention: Score I (risk score for postoperative vomiting)
Number of subjects: 1091
Study 9605364 — intervention group
Group type: EXPERIMENTAL
Intervention: Score II (new risk score for postoperative vomiting)
Number of subjects: 1091
Study 7812305 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiuggi water (more than 1500 ml/die) for 7 and 14 days
Number of subjects: 200
Study 7812305 — intervention group
Group type: COMPARATOR
Intervention: Fiuggi water (less than 1500 ml/die) for 7 and 14 days
Number of subjects: 200
Study 2978287 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein meal (1-1.5 g of protein/kg)
Number of subjects: 10
Study 2978287 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate meal (similar caloric, sodium, and potassium content)
Number of subjects: 10
Study 30230088 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation (CBA)
Number of subjects: 210
Study 30230088 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency catheter ablation (RFCA)
Number of subjects: 210
Study 28260593 — intervention group
Group type: EXPERIMENTAL
Intervention: Seven-point grading scale (autumn semester)
Number of subjects: 1037
Study 28260593 — intervention group
Group type: EXPERIMENTAL
Intervention: Pass/fail approach (spring semester)
Number of subjects: 1037
Study 28260593 — intervention group
Group type: COMPARATOR
Intervention: International students (control group)
Number of subjects: 1037
Study 25556038 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI group (177 patients)
Number of subjects: 266
Study 25556038 — intervention group
Group type: COMPARATOR
Intervention: Control group (89 patients)
Number of subjects: 266
Study 23639612 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker-based diagnostic strategy (aspergillus galactomannan and PCR)
Number of subjects: 240
Study 23639612 — intervention group
Group type: COMPARATOR
Intervention: Standard diagnostic strategy (culture and histology)
Number of subjects: 240
Study 20694508 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Cognitive-Behavioral Therapy (FCBT)
Number of subjects: 50
Study 20694508 — intervention group
Group type: COMPARATOR
Intervention: Individual Cognitive-Behavioral Therapy (ICBT)
Number of subjects: 50
Study 19652948 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 500
Study 19652948 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone
Number of subjects: 500
Study 16879931 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 2400 mg/day
Number of subjects: 6
Study 16879931 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 3200 mg/day
Number of subjects: 6
Study 16879931 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine (0, 12, 25, 50 mg)
Number of subjects: 6
Study 16879931 — intervention group
Group type: COMPARATOR
Intervention: Gabapentin 0 mg/day (placebo)
Number of subjects: 6
Study 15319143 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg Mg++ daily (group A)
Number of subjects: 110
Study 15319143 — intervention group
Group type: COMPARATOR
Intervention: No supplement (group B)
Number of subjects: 110
Study 11466190 — intervention group
Group type: EXPERIMENTAL
Intervention: Photopheresis
Number of subjects: 40
Study 11466190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9580800 — intervention group
Group type: EXPERIMENTAL
Intervention: metronidazole 2%
Number of subjects: 34
Study 9580800 — intervention group
Group type: EXPERIMENTAL
Intervention: permethrin 1%
Number of subjects: 34
Study 9580800 — intervention group
Group type: EXPERIMENTAL
Intervention: sublimed sulphur 10%
Number of subjects: 34
Study 9580800 — intervention group
Group type: EXPERIMENTAL
Intervention: lindane 1%
Number of subjects: 34
Study 9580800 — intervention group
Group type: EXPERIMENTAL
Intervention: crotamiton 10%
Number of subjects: 34
Study 9580800 — intervention group
Group type: EXPERIMENTAL
Intervention: benzyl benzoate (BB) 10%
Number of subjects: 34
Study 7923309 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril 10 mg twice daily (increased to 20 mg twice daily if necessary)
Number of subjects: 74
Study 7923309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 7923309 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril
Number of subjects: 74
Study 3044508 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 18
Study 3044508 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 18
Study 3044508 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cholestyramine and bezafibrate
Number of subjects: 18
Study 31974533 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat treatment after 5 months
Number of subjects: 51
Study 31974533 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat treatment after 11.2 months
Number of subjects: 51
Study 29228517 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face CBT-BN
Number of subjects: 179
Study 29228517 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based CBT-BN
Number of subjects: 179
Study 28126491 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-nutritive sweetened beverage (NSB; sucralose; 4 g)
Number of subjects: 21
Study 28126491 — intervention group
Group type: COMPARATOR
Intervention: Sugar-sweetened beverage (SSB; sucrose; 31 g)
Number of subjects: 21
Study 26006702 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg oral immediate-release onapristone after an overnight fast
Number of subjects: 12
Study 26006702 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg oral immediate-release onapristone within 30 min of a high-fat, high-calorie meal
Number of subjects: 12
Study 26006702 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg oral immediate-release onapristone
Number of subjects: 12
Study 23663191 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance training
Number of subjects: 34
Study 23663191 — intervention group
Group type: COMPARATOR
Intervention: Stay active (Control)
Number of subjects: 34
Study 20367670 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed dye laser therapy after 60-90 min ALA application
Number of subjects: 44
Study 20367670 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated side)
Number of subjects: 44
Study 18419537 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz-based regimens with 2 or 3 NRTIs
Number of subjects: 0
Study 16308351 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous isoproterenol (isoprenaline): 6, 12 and 24 ng (kg fat‐free mass)‐1 min‐1
Number of subjects: 39
Study 16308351 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (vitamin C; 0.04 g (kg fat‐free mass)‐1)
Number of subjects: 39
Study 14515011 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise (treadmill running at 60, 75, 90, and 100% VO(2 max))
Number of subjects: 0
Study 14515011 — intervention group
Group type: COMPARATOR
Intervention: Control trial (resting)
Number of subjects: 0
Study 11185026 — intervention group
Group type: EXPERIMENTAL
Intervention: New tailored walking campaigns
Number of subjects: 181
Study 11185026 — intervention group
Group type: COMPARATOR
Intervention: English Health Education Authority (HEA) 'Active for Life' campaign
Number of subjects: 181
Study 9088775 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Lispro (LP)
Number of subjects: 12
Study 9088775 — intervention group
Group type: COMPARATOR
Intervention: Human Insulin (H)
Number of subjects: 12
Study 9088775 — intervention group
Group type: COMPARATOR
Intervention: Porcine Insulin (P)
Number of subjects: 12
Study 8462534 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diclofenac, 100 mg
Number of subjects: 169
Study 8462534 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 169
Study 3517396 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (geriatric consultation team)
Number of subjects: 185
Study 3517396 — intervention group
Group type: COMPARATOR
Intervention: Control group (no geriatric consultation team)
Number of subjects: 185
Study 29905973 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide 20 μg/d plus sham vibration 10 min/d (n=20)
Number of subjects: 61
Study 29905973 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus vibration 10 min/d (n=20)
Number of subjects: 61
Study 29905973 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide 20 μg/d plus vibration 10 min/d (n=21)
Number of subjects: 61
Study 29905973 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide 20 μg/d after 12-month extension
Number of subjects: 61
Study 29905973 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups after 12-month extension
Number of subjects: 61
Study 26250786 — intervention group
Group type: EXPERIMENTAL
Intervention: White Diet
Number of subjects: 226
Study 26250786 — intervention group
Group type: COMPARATOR
Intervention: Clear-fluid diet
Number of subjects: 226
Study 26250786 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-dose regimen
Number of subjects: 226
Study 26250786 — intervention group
Group type: EXPERIMENTAL
Intervention: Day-before regimen
Number of subjects: 226
Study 25207759 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature-modulated photodynamic therapy (PDT) with 20% ALA and 10 J/cm, 417-nm blue light, heated during incubation
Number of subjects: 20
Study 25207759 — intervention group
Group type: COMPARATOR
Intervention: Control side (not heated)
Number of subjects: 20
Study 25207759 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature-modulated PDT
Number of subjects: 20
Study 22776824 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 1 mg
Number of subjects: 282
Study 22776824 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 2.5 mg
Number of subjects: 282
Study 22776824 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg
Number of subjects: 282
Study 22776824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 282
Study 22776824 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (all doses)
Number of subjects: 282
Study 22776824 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 282
Study 20055989 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower tidal volume (6 ml/kg)
Number of subjects: 150
Study 20055989 — intervention group
Group type: COMPARATOR
Intervention: Conventional tidal volume (10 ml/kg)
Number of subjects: 150
Study 17849474 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 65
Study 17849474 — intervention group
Group type: COMPARATOR
Intervention: Transfusion
Number of subjects: 65
Study 15699275 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (ET)
Number of subjects: 45
Study 15699275 — intervention group
Group type: COMPARATOR
Intervention: Control group (inactive)
Number of subjects: 45
Study 12745558 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg vitamin C twice daily until 34 weeks' gestation
Number of subjects: 0
Study 12745558 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching)
Number of subjects: 0
Study 10784581 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy screening at 3-year intervals
Number of subjects: 252
Study 10784581 — intervention group
Group type: COMPARATOR
Intervention: No screening (control)
Number of subjects: 252
Study 10784581 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy screening in mutation-positive subjects
Number of subjects: 252
Study 10784581 — intervention group
Group type: COMPARATOR
Intervention: No screening in mutation-positive subjects (control)
Number of subjects: 252
Study 10784581 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy screening
Number of subjects: 252
Study 8810613 — intervention group
Group type: EXPERIMENTAL
Intervention: AutoSet nCPAP titration
Number of subjects: 21
Study 8810613 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual titration
Number of subjects: 21
Study 8810613 — intervention group
Group type: COMPARATOR
Intervention: Conventional fixed-pressure nCPAP
Number of subjects: 21
Study 8810613 — intervention group
Group type: COMPARATOR
Intervention: Diagnostic night
Number of subjects: 21
Study 1448529 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid expansion (every day)
Number of subjects: 23
Study 1448529 — intervention group
Group type: COMPARATOR
Intervention: Slow expansion (every week)
Number of subjects: 23
Study 4020121 — intervention group
Group type: EXPERIMENTAL
Intervention: timolol (10 mg/day, n = 14)
Number of subjects: 30
Study 4020121 — intervention group
Group type: EXPERIMENTAL
Intervention: methyldopa (250 mg/day, n = 16)
Number of subjects: 30
Study 4020121 — intervention group
Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide (25 mg/day) and amiloride (2.5 mg/day)
Number of subjects: 30
Study 4020121 — intervention group
Group type: EXPERIMENTAL
Intervention: timolol (n = 7)
Number of subjects: 30
Study 4020121 — intervention group
Group type: EXPERIMENTAL
Intervention: methyldopa (n = 16)
Number of subjects: 30
Study 30884215 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutual Information (MI)
Number of subjects: 0
Study 30884215 — intervention group
Group type: EXPERIMENTAL
Intervention: Variation of Information (VI)
Number of subjects: 0
Study 30884215 — intervention group
Group type: EXPERIMENTAL
Intervention: Window size of at least 120 s
Number of subjects: 0
Study 28846562 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time BandCizer™-iPad feedback on contraction time
Number of subjects: 40
Study 28846562 — intervention group
Group type: COMPARATOR
Intervention: Control group (no feedback)
Number of subjects: 40
Study 26729245 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic therapy (hydroxychloroquine, methotrexate, mycophenolate mofetil, prednisolone) in addition to standard topical therapy
Number of subjects: 96
Study 26729245 — intervention group
Group type: COMPARATOR
Intervention: Topical therapy plus a short course of prednisolone given orally
Number of subjects: 96
Study 25246739 — intervention group
Group type: EXPERIMENTAL
Intervention: ICO group using one icodextrin‐containing and two glucose‐containing dialysates (n=41)
Number of subjects: 80
Study 25246739 — intervention group
Group type: COMPARATOR
Intervention: GLU group continuously using four glucose‐containing dialysates (n=39)
Number of subjects: 80
Study 25246739 — intervention group
Group type: EXPERIMENTAL
Intervention: ICO group
Number of subjects: 80
Study 25246739 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 22475108 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 7
Study 22475108 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical debridement and sequestrectomy
Number of subjects: 7
Study 20150905 — intervention group
Group type: EXPERIMENTAL
Intervention: Equoral
Number of subjects: 99
Study 20150905 — intervention group
Group type: COMPARATOR
Intervention: Neoral
Number of subjects: 99
Study 17914310 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusidic acid (4 mg/mL) and heparin (10 IU/mL) lock
Number of subjects: 103
Study 17914310 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fusidic acid-heparin lock)
Number of subjects: 103
Study 16182311 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 50 mg i.v. eight hourly
Number of subjects: 141
Study 16182311 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate 1 g six hourly
Number of subjects: 141
Study 16182311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 11583670 — intervention group
Group type: EXPERIMENTAL
Intervention: Photorefractive keratectomy (PRK)
Number of subjects: 45
Study 11583670 — intervention group
Group type: COMPARATOR
Intervention: Laser in situ keratomileusis (LASIK)
Number of subjects: 45
Study 9728918 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional MRI testing of a cortical region straddling the right lingual sulcus for building perception.
Number of subjects: 0
Study 9728918 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiments discounting alternative explanations for the behavior of the identified site.
Number of subjects: 0
Study 7976758 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-assisted liposuction
Number of subjects: 51
Study 3592003 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 44
Study 3592003 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 44
Study 3592003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 29632995 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimodulin (42 mg IgM/kg/day)
Number of subjects: 160
Study 29632995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 29632995 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimodulin
Number of subjects: 160
Study 27537999 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriene (Cal) 0.005% plus betamethasone dipropionate (BD) 0.064% aerosol foam
Number of subjects: 426
Study 27537999 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 426
Study 24122814 — intervention group
Group type: EXPERIMENTAL
Intervention: CSL112 (3.4 g or 6.8 g, administered intravenously once or twice weekly)
Number of subjects: 36
Study 24122814 — intervention group
Group type: EXPERIMENTAL
Intervention: CSL112 (multiple infusions)
Number of subjects: 36
Study 24122814 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered intravenously)
Number of subjects: 36
Study 23286932 — intervention group
Group type: EXPERIMENTAL
Intervention: In-plane technique
Number of subjects: 81
Study 23286932 — intervention group
Group type: COMPARATOR
Intervention: Out-of-plane technique
Number of subjects: 81
Study 21219987 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 μg of haemagglutinin (HA) of each of three influenza strains on days 0 and 14
Number of subjects: 1349
Study 21219987 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 μg of haemagglutinin (HA) on day 0 and saline placebo on day 14
Number of subjects: 1349
Study 21219987 — intervention group
Group type: COMPARATOR
Intervention: Placebo on days 0 and 14
Number of subjects: 1349
Study 21219987 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccine dose groups
Number of subjects: 1349
Study 19346228 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeptin
Number of subjects: 224
Study 19346228 — intervention group
Group type: COMPARATOR
Intervention: BNP
Number of subjects: 224
Study 19346228 — intervention group
Group type: COMPARATOR
Intervention: NT-proBNP
Number of subjects: 224
Study 17001147 — intervention group
Group type: EXPERIMENTAL
Intervention: SPETA (Standardized Physical Examination Teaching Associates)
Number of subjects: 144